Menu
X

Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – Short-term efficacy

🎉Another BCMA CAR-T therapy for multiple myeloma hits the market in China!

– Short-term efficacy ✨

multiple myeloma

multiple myeloma

💪China  CAR-T therapy

    In recent years, CAR-T cell therapy has achieved tremendous success in treating hematologic malignancies. Over the past 11 years, China has seen a surge in clinical trials evaluating the safety and efficacy of CAR-T therapy. China has now surpassed the United States as a major force in CAR-T clinical research. 🌟

🚀In the field of multiple myeloma (MM),

    China has gained regulatory approval from the NMPA for two fully human BCMA CAR-T therapies for the treatment of relapsed/refractory MM (R/R MM). These therapies are Equecabtagene Autoleucel and Zevorcabtagene Autoleucel. 💉

🩺BCMA

    While both therapies target the same BCMA and share a common co-stimulatory domain, there are some fundamental differences between them. Zevorcabtagene Autoleucel includes patients with stable disease after previous treatment, whereas Equecabtagene Autoleucel focuses on patients with relapsed or progressive MM. 🎯

📈Looking at the short-term efficacy

    The median time to peak CAR-T cells in peripheral blood is 12 days for Equecabtagene Autoleucel and 14 days for Zevorcabtagene Autoleucel. This indicates that the former can rapidly exert its effect, potentially laying the foundation for achieving clinical remission faster and better. 💥
📆Clinical trial results seem to support this notion, with Equecabtagene Autoleucel showing a median time to response (TTR) of 15 days, compared to 29 days for Zevorcabtagene Autoleucel. At the 3-month follow-up, the complete remission rates were 40.3% for Equecabtagene Autoleucel in the registered clinical trial FUMANBA-1 1b/2 phase, surpassing the rate of 28.3% observed in the registered clinical trial LUMMICAR-1 phase 2 for Zevorcabtagene Autoleucel. 📊
💉It’s worth noting that the infusion dose for Equecabtagene Autoleucel is 1×106 cells/kg, while the total infusion dose for Zevorcabtagene Autoleucel is 150×106 cells, which translates to double the dose of Equecabtagene Autoleucel for patients with a weight of 70kg-75kg. Additionally, the reinfusion dose for Zevorcabtagene Autoleucel is not fixed and needs to be increased to 1.8×108 cells for patients weighing ≥80kg. ⚖️
🌈With the increasing availability of these groundbreaking BCMA CAR-T therapies, the landscape of multiple myeloma treatment continues to expand, offering more possibilities and choices. 🔬
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.